Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.
Here's what you need to know now for Wednesday, Feb. 14.
Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.
Wow. Corporate America is sitting on massive amounts of cash that could be unleashed on deals, according to new research from Citi.
Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
Large-cap healthcare stocks, especially those in the medical technology sector, are one of the biggest losers in the recent market selloff.
TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.